Form 4: Pacira Director Schedules Future Stock Sale Under 10b5-1 Plan

Pacira BioSciences Director Abraham Ceesay has scheduled the sale of 2,354 shares of common stock for September 4, 2025, at a price of $27.19 per share, under a pre-arranged 10b5-1 trading plan.

Summary

• Abraham Ceesay, a Director of Pacira BioSciences, Inc. (PCRX), reported a planned future sale of common stock.
• The transaction is scheduled to occur on September 4, 2025.
• A total of 2,354 shares of common stock will be disposed of at a price of $27.19 per share.
• Following this planned transaction, Ceesay's direct beneficial ownership will be 9,039 shares.
• The sale is being conducted pursuant to a Rule 10b5-1 trading plan, which was previously adopted by the reporting person.

Sentiment

Score: 5

Explanation: The filing reports a future, pre-scheduled sale of shares by a director under a Rule 10b5-1 trading plan. Such plans are established in advance and are not typically indicative of the insider's current sentiment about the company's prospects, making the transaction neutral in terms of immediate sentiment.

Future Outlook

This Form 4 filing reports a specific insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction under a pre-arranged plan and does not provide information that directly relates to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders will note the director's planned future sale of shares. As it is under a 10b5-1 plan, it is generally viewed as a routine personal financial management event rather than a signal of company performance.

Key Dates

Recommendation

The Form 4 discloses a future, pre-planned sale of shares by a director under a Rule 10b5-1 plan. This type of transaction is typically for personal financial planning and does not inherently reflect a change in the company's fundamentals or the director's long-term view. Therefore, this filing alone does not provide a basis to change an existing investment recommendation.

Keywords

Pacira BioSciences, PCRX, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan, Future Transaction